Published in J Pharmacol Exp Ther on October 01, 1959
Tetrabenazine. Nat Rev Drug Discov (2009) 1.60
A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors. Br J Pharmacol (1972) 1.10
Brain dopamine and serotonin differ in regulation and its consequences. Proc Natl Acad Sci U S A (2012) 1.00
Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev (2010) 0.99
Tetrabenazine in the treatment of Huntington's disease. Neuropsychiatr Dis Treat (2007) 0.99
THE INCREASE IN THE TOXICITY OF YOHIMBINE INDUCED BY IMIPRAMINE AND OTHER DRUGS IN MICE. Br J Pharmacol Chemother (1963) 0.89
Using the affective bias test to predict drug-induced negative affect: implications for drug safety. Br J Pharmacol (2017) 0.80
Reserpine has a direct action as a calcium antagonist on mammalian smooth muscle cells. J Physiol (1983) 0.79
Effect of tetrabenazine and alpha-methyl-m-tyrosine on exploratory activity and brain catecholamines in rats. Br J Pharmacol (1971) 0.79
An examination of the action of tetrabenazine on peripheral noradrenergic neurones [proceedings]. Br J Pharmacol (1977) 0.78
Role of catecholamines in the central mechanism of emetic response induced by peruvoside and ouabain in cats. Br J Pharmacol (1975) 0.78
Effect of tetrabenazine on motor function in patients with huntington disease. Neurol Ther (2012) 0.76
The mode of action of tetrabenazine on peripheral noradrenergic nerves. Br J Pharmacol (1977) 0.76
Tremor induced by tetrabenazine. Br J Pharmacol (1969) 0.75
A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem (1952) 18.27
A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther (1959) 16.61
The physiological disposition and metabolic fate of hydrocortisone in man. J Clin Invest (1955) 6.74
Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem (1954) 5.08
Identification and assay of serotonin in brain. J Pharmacol Exp Ther (1956) 4.17
The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther (1957) 3.99
The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1953) 3.60
A chemical method for the determination of free choline in plasma. J Biol Chem (1953) 3.57
Norepinephrine depletion as a possible mechanism of action of guanethidine (SU 5864), a new hypotensive agent. Proc Soc Exp Biol Med (1960) 3.26
On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther (1959) 3.16
Some physico-chemical factors in drug action. J Pharm Pharmacol (1957) 3.13
The fate of antipyrine in man. J Pharmacol Exp Ther (1950) 3.05
Serotonin release as a possible mechanism of reserpine action. Science (1955) 3.03
The direct determination of phosphatidyl ethanolamine and phosphatidyl serine in plasma and red blood cells. J Biol Chem (1953) 2.98
Ascorbic acid in aromatic hydroxylation. II. Products formed by reaction of substrates with ascorbic acid, ferrous ion, and oxygen. J Biol Chem (1954) 2.78
INTERACTION OF GUANETHIDINE WITH ADRENERGIC NEURONS. J Pharmacol Exp Ther (1965) 2.77
A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann N Y Acad Sci (1957) 2.71
Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther (1958) 2.62
The fate of aminopyrine (pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material. J Pharmacol Exp Ther (1950) 2.54
The oxidation of drugs by liver microsomes: on the role of TPNH and oxygen. J Pharmacol Exp Ther (1957) 2.46
The fate of pentobarbital in man and dog and a method for its estimation in biological material. J Pharmacol Exp Ther (1953) 2.38
Identification and chemical assay of norepinephrine in brain and other tissues. J Pharmacol Exp Ther (1958) 2.37
Enzymatic metabolism of drugs and other foreign compounds. Annu Rev Biochem (1958) 2.36
Serotonin as a mediator of reserpine action in brain. J Pharmacol Exp Ther (1956) 2.26
A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther (1957) 2.20
Detoxication of drugs and other foreign compounds by liver microsomes. Science (1955) 2.20
Estimation of intracellular water in man. Am J Physiol (1950) 2.14
Evidence that serotonin has a role in brain function. Science (1955) 2.13
Pharmacological consequences of the selective release of peripheral norepinephrine by syrosingopine (Su 3118). J Pharmacol Exp Ther (1960) 2.10
The fate of thiopental in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1950) 2.10
Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science (1955) 1.99
Absorption of drugs from the stomach. I. The rat. J Pharmacol Exp Ther (1957) 1.86
Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther (1957) 1.85
Mechanism of the potentiating action of beta-diethylaminoethyl diphenylpropylacetate. J Pharmacol Exp Ther (1954) 1.78
Enzymatic dealkylation of aminopyrine (pyramidon) and other alkylamines. J Biol Chem (1955) 1.77
The metabolic fate of phenylbutazone (butazolidin) in man. J Pharmacol Exp Ther (1955) 1.76
The physiological disposition and metabolic fate of cortisone in man. J Clin Invest (1957) 1.62
On the mechanism of drug potentiation by iproniazid (2-isopropyl-1-isonicotinyl hydrazine). J Pharmacol Exp Ther (1956) 1.61
Physiological disposition and fate of chlorpromazine and a method for its estimation in biological material. J Pharmacol Exp Ther (1956) 1.59
BINDING AND RELEASE OF METARAMINOL: MECHANISM OF NOREPINEPHRINE DEPLETION BY ALPHA-METHYL-M-TYROSINE AND RELATED AGENTS. J Pharmacol Exp Ther (1964) 1.56
The enzymatic metabolism of hexobarbital (evipal). J Pharmacol Exp Ther (1955) 1.56
Possible interrelationship between release of brain norepinephrine and serotonin by reserpine. Science (1957) 1.54
Release of serotonin and catecholamines by drugs. Pharmacol Rev (1962) 1.53
Total body water in man. Am J Physiol (1950) 1.50
Inhibitory effects of beta-diethylaminoethyl diphenylpropylacetate on a variety of drug metabolic pathways in vitro. J Pharmacol Exp Ther (1954) 1.49
The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther (1960) 1.47
RECENT VIEWS ON MECHANISMS FOR LOWERING SYMPATHETIC TONE. Circulation (1963) 1.44
On the mechanism of antidepressant action of imipraminelike drugs. Ann N Y Acad Sci (1962) 1.42
The use of procaine amide in cardiac arrhythmias. Circulation (1951) 1.42
Pathways of drug metabolism. J Pharm Pharmacol (1956) 1.41
Biochemical and pharmacological effects of the monoamine oxidase inhibitors, iproniazid, 1-phenyl-2-hydrazinopropane (JB 516) and 1-phenyl-3-hydrazinobutane (JB 835). J Pharmacol Exp Ther (1960) 1.41
The mechanism of serotonin and catecholamine uptake by platelets. J Pharmacol Exp Ther (1959) 1.40
Role of brain serotonin in reserpine action. Ann N Y Acad Sci (1957) 1.40
Structural requirements for bretylium and guanethidine-like activity. Life Sci (1962) 1.39
Release of serotonin from blood platelets by reserpine in vitro. J Pharmacol Exp Ther (1957) 1.39
The enzymatic reduction of chloramphenicol, p-nitrobenzoic acid and other aromatic nitro compounds in mammals. J Pharmacol Exp Ther (1957) 1.38
Metabolism of drugs in subjects with Laennec's cirrhosis. Med Exp Int J Exp Med (1959) 1.38
Postoperative pain; its use in the comparative evaluation of analgesics. Surgery (1952) 1.38
Assay of serotonin and related metabolites, enzymes, and drugs. Methods Biochem Anal (1958) 1.37
Microanalytical procedures for fluorometric assay of brain DOPA-5HTP decarboxylase, norepinephrine and serotonin, and a detailed mapping of decarboxylase activity in brain. J Neurochem (1961) 1.35
The physiological disposition and biotransformation of dibenamine and a method for its estimation in biological tissues. J Pharmacol Exp Ther (1952) 1.35
RELEASE OF METARAMINOL (ARAMINE) FROM THE HEART BY SYMPATHETIC NERVE STIMULATION. Science (1964) 1.33
The role of body fat in limiting the duration of action of thiopental. J Pharmacol Exp Ther (1952) 1.32
MECHANISM OF ACTION OF RESERPINE AND INSULIN ON GASTRIC AMINES AND GASTRIC ACID SECRETION, AND THE EFFECT OF MONOAMINE OXIDASE INHIBITION. J Pharmacol Exp Ther (1963) 1.28
Reserpine and guanethidine action on peripheral stores of catecholamines. Life Sci (1962) 1.27
Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone. Am J Med (1954) 1.22
Effects of reserpine and cold-exposure on pituitary-adrenocortical function in rats. J Pharmacol Exp Ther (1961) 1.21
THE ACTIONS OF RESERPINE, GUANETHIDINE AND METARAMINOL ON CARDIAC CATECHOLAMINE STORES. Life Sci (1964) 1.18
Effect of desoxycorticosterone on the colon; its relation to the action of cation exchange resins in man. Proc Soc Exp Biol Med (1951) 1.18
Enzymatic reduction of prontosil and other azo dyes. J Pharmacol Exp Ther (1957) 1.17
The physiological disposition of dicumarol in man. J Pharmacol Exp Ther (1950) 1.17
Interaction of monoamine oxidase inhibitors with physiological and biochemical mechanisms in brain. Ann N Y Acad Sci (1959) 1.17
Role for ganglionic norepinephrine in sympathetic synaptic transmission. Science (1961) 1.15
Interaction of drugs with norepinephrine in the brain. Pharmacol Rev (1959) 1.15
Quinoline and its transformation products found in urine. J Biol Chem (1950) 1.14
Storage synthesis, and metabolism of monoamines in the developing brain. J Neurochem (1962) 1.14
Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia (1955) 1.14
Comparative effects of monoamine oxidase inhibitors on monoamine oxidase and diamine oxidase. Biochem Pharmacol (1960) 1.14
On the mechanism of action of reserpine: effect of reserpine on capacity of tissues to bind serotonin. J Pharmacol Exp Ther (1957) 1.13
Inhibition of drug metabolic pathways by the potentiating agent, 2, 4-dichloro-6-phenyl-phenoxyethyl diethylamine. J Pharmacol Exp Ther (1955) 1.11
Relationship between the lipid solubility of drugs and their oxidation by liver microsomes. Biochem Pharmacol (1959) 1.10
Biochemical pharmacological considerations of phenylbutazone and its analogues. Ann N Y Acad Sci (1960) 1.08
The biotransformation of ethyl biscoumacetate (tromexan) in man, rabbit and dog. J Pharmacol Exp Ther (1953) 1.08